Company Profile
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Latest News
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
Billionaire Ramaswamy's wealth has surged as he runs for Ohio governor
ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?
| Sector | Healthcare |
| Industry | Biotechnology |
| Website | https://roivant.com |
| Audit Risk | 5 |
| Board Risk | 7 |
| Overall Risk | 9 |
| Market Cap | 25.18B |
| Forward P/E | -22.45 |
| Trailing Annual Div. Rate | 0 |
| Trailing Annual Div. Yield | 0.00% |
| Trailing EPS | -0.54 |
| Forward EPS | -1.56 |
| Book Value | 6.29 |
| Price-to-Book | 5.57 |
| Enterprise-to-Revenue | 2,634.66 |
| Enterprise-to-EBITDA | -17.05 |
| Short Ratio | 5.83 |
| Earnings Date | 08/06/2026 |
| Earnings Call Date | |
| Earnings Average | -0.36 |
| Earnings Low | -0.47 |
| Earnings High | -0.27 |
| Revenue Average | 2.34M |
| Revenue Low | 0 |
| Revenue High | 5.00M |